India's Cipla rises after USFDA approval for cancer drug

Shares of Cipla Ltd CIPL.NS rises around 3%

Stock had risen 5.2% to 1,488.50 rupees earlier in the session

Pharma co gets final approval from the United States Food and Drug Administration (USFDA) for cancer treatment drug Protein-bound Paclitaxel

Stock fell 1.2% in previous session

More than 1.7 mln shares traded as of 1:44 p.m. IST, more than their 30-day moving avg of over 1.5 mln shares
Mean rating of stock is 'buy'; their median PT is 1,640 rupees - data compiled by LSEG
Day's gains trims CIPL's YTD losses to 7.4% vs a 12.5% fall in Nifty pharma index .NIPHARM